Gilead Sciences Inc
GILD: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $18.00 | Mdq | Fwskvffp |
Gilead's HIV Dominance and Growing Oncology Portfolio Support a Wide Moat
/s3.amazonaws.com/arc-authors/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
Business Strategy and Outlook
Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and pipeline support a wide moat, but Gilead needs HCV market stabilization, strong continued innovation in HIV, solid pipeline data, and smart future acquisitions to return to growth.